Finally, WT1 reoccurrence predicts morphological relapse also in the setting of allo-HSCT: Candoni et al. [48] analyzed WT1 expression after allo-HSCT in 38 AML, demonstrating a concordance between BM WT1, chimerism and molecular MRD, with a CIR of 100% in patients with BM WT1 levels >70 × 10−4; Pozzi et al. analyzed BM WT1 in 122 AML patients before and after allo-HSCT, demonstrating higher CIR (HR: 2.3, p = 0.002) in patients with BM WT1 >100/104 ABL copies. Here, WT1 is linked to acute myeloid leukemia.